Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron

Intravenous ferric carboxymaltose () improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after administration in pat...

Descripción completa

Detalles Bibliográficos
Autores: Núñez, Julio|||0000-0003-1672-7119, Miñana, Gema|||0000-0001-8777-2588, Cardells, Ingrid, Palau, Patricia|||0000-0001-5040-0924, Llàcer, Pau, Facila Rubio, Lorenzo|||0000-0003-1402-4364, Almenar Bonet, Luis|||0000-0002-7710-361X, López-Lereu, Maria P., Monmeneu, Jose V., Amiguet, Martina, González, Jessika, Serrano, Alicia, Montagud, Vicente, López-Vilella, Raquel, Valero, Ernesto, García-Blas, Sergio, Bodi, Vicente|||0000-0001-6425-5828, De la Espriella, Rafael|||0000-0002-8720-3999, Lupón, Josep|||0000-0002-5601-9611, Navarro, Jorge, Górriz, José Luis, Sanchis, Juan|||0000-0003-0797-8709, Chorro, Francisco J., Comín-Colet, Josep|||0000-0001-8780-720X, Bayés-Genís, Antoni|||0000-0002-3044-197X
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:226272
Acceso en línea:https://ddd.uab.cat/record/226272
https://dx.doi.org/urn:doi:10.1161/JAHA.119.014254
Access Level:acceso abierto
Palabra clave:Cardiac magnetic resonance
Ferric carboxymaltose
Heart failure
Iron deficiency
Myocardial iron
Descripción
Sumario:Intravenous ferric carboxymaltose () improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after administration in patients with heart failure and iron deficiency using cardiac magnetic resonance. Fifty-three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive intravenous or placebo in a multicenter, double-blind study. T2* and T1 mapping cardiac magnetic resonance sequences, noninvasive surrogates of intramyocardial iron, were evaluated before and 7 and 30 days after randomization using linear mixed regression analysis. Results are presented as least-square means with 95% CI. The primary end point was the change in T2* and T1 mapping at 7 and 30 days. Median age was 73 (65-78) years, with N-terminal pro-B-type natriuretic peptide, ferritin, and transferrin saturation medians of 1690 pg/mL (1010-2828), 63 ng/mL (22-114), and 15.7% (11.0-19.2), respectively. Baseline T2* and T1 mapping values did not significantly differ across treatment arms. On day 7, both T2* and T1 mapping (ms) were significantly lower in the arm (36.6 [34.6-38.7] versus 40 [38-42.1], P =0.025; 1061 [1051-1072] versus 1085 [1074-1095], P =0.001, respectively). A similar reduction was found at 30 days for T2* (36.3 [34.1-38.5] versus 41.1 [38.9-43.4], P =0.003), but not for T1 mapping (1075 [1065-1085] versus 1079 [1069-1089], P =0.577). In patients with heart failure and iron deficiency, administration was associated with changes in the T2* and T1 mapping cardiac magnetic resonance sequences, indicative of myocardial iron repletion. : . Unique identifier: 03398681.

Similares en LA Referencia